Challenging and Defending BioPharma Patents at the PTAB – What Practitioners Need to Know

August 13, 2014

IPR and CBM petitions present unique opportunities and issues in the biopharma area for both branded and generic companies. The number of petitions being filed in this area is growing steadily. Listen in as we explored strategic issues related to post-grant practice, Hatch-Waxman litigation, and biosimilars.

Dorothy Whelan, Principal and Post-Grant Practice Co-Chair, Twin Cities
Gwilym Attwell, Principal, Delaware
Download Presentation Slides
For audio-only (MP3 format), click here to launch in a new window, or right-click and choose “Save link/target as” to download to your computer.

< Main Webinar Page